The Canadian Association for the Study of the Liver (CASL) and the Canadian Liver Foundation (CLF) acknowledge the following organizations for their support of our mission of “bringing liver research to life” to benefit the liver health of all Canadians through research, education, patient support and advocacy:

In keeping with the Canadian Medical Association Guidelines, program content and selection of speakers are the sole responsibility of the Scientific Committee. Funders have had no input into the content, speakers or activities of the meeting.
On behalf of the Organizing Committee, Canadian Association for the Study of the Liver and Canadian Liver Foundation, it is a pleasure to welcome you to the 2018 Canadian Association for the Study of the Liver-Single Topic Conference on Decompensated Cirrhosis-From Clinic to Transplant.

We are bringing together physicians, researchers, allied health professionals and industry members to discuss and learn the challenges in managing patients with decompensated cirrhosis. The goal of this conference is to review the current understanding, raise awareness, identify challenges and determine knowledge gaps which need to be investigated, therefore fostering research collaborations within and beyond Canada.

Our aim is to provide a platform for exchanging information, views, opinions and sharing ideas between experts, leaders as well as new fellows and investigators in the field. We hope this forum will serve as a strong impetus for further collaborative initiatives that will help improve the management of patients with decompensated cirrhosis.

We wish you a stimulating conference!

Sincerely,
Scientific Co-Chairs,

Dr. Christopher F. Rose, PhD
Research Professor
Director of Hepato-neuro laboratory
Dept. Medicine, Université de Montréal
CRCHUM

Constantine J. Karvellas, MD, SM, FRCPC, FCCM
Associate Professor of Medicine
Division of Gastroenterology (Liver Unit)
Dept. of Critical Care Medicine
Adjunct, School of Public Health Sciences
University of Alberta
Decompensated cirrhosis is characterized by a sudden deterioration of chronic liver disease that may result in multi-organ failure. This increasingly recognized entity can develop at any time during the course of liver disease and it is associated with high short term mortality. Our understanding of the determinants of decompensated cirrhosis and the availability of effective therapeutic options remain limited. It is therefore imperative that the level of knowledge and recognition of this syndrome be increased. A multi-pronged approach is required to adequately address this syndrome from the perspectives of prevention, diagnosis, management, treatment and research.

Upon completion of the conference, participants will be able to:

- **Recognize** the current status of epidemiology, pathophysiology, diagnosis, clinical presentation, and therapy of decompensated cirrhosis.
- **Identify** gaps in our current understanding of decompensated cirrhosis that need to be filled by future research.

Furthermore, the knowledge gained from this meeting can be applied and enhanced as the interactive format of the meeting will strive to:

- Foster **informal exchange** between leaders in the field and engage young investigators.
- Foster **research collaboration** on decompensated cirrhosis within Canada, North America and beyond.
Organizing team

Organizing committee
Christopher Rose
Dean Karvellas
Rick Schreiber
Julien Bissonnette

Association partners

Event manager
Liette Philippe

Local organizing committee
Mariana Oliveira
Mélanie Tremblay

On-site work force
Cassandra Picinbono-Larose
Gregory Petrazzo
Mariana Oliveira
Mimosa Nguyen
Mélanie Tremblay
Rafael Ochoa-Sanchez
## Schedule-at-a-glance

### Friday October 12<sup>th</sup>
- **17:00-18:30** Onsite Registration
  - Main lobby of hotel
- **17:00-19:00** Welcome Reception
  - Ironstone Grill
- **19:00-22:00** Dinner & Keynote
  - Ironstone Grill

### Saturday October 13<sup>th</sup>
- **07:00-08:00** Breakfast and Onsite Registration
  - Celtic Foyer
- **08:00-12:00** Morning Sessions
  - Celtic Ballroom
- **12:00-13:30** Lunch
  - Celtic Foyer
- **13:30-18:00** Afternoon Sessions
  - Celtic Ballroom
  - Breakout session A
    - 1. Mulligan
    - 2. RTJ
- **19:00-19:45** Reception
  - Celtic Foyer
- **19:45-22:30** Dinner & Keynote
  - Celtic Ballroom

### Sunday October 14<sup>th</sup>
- **07:00-08:00** Breakfast
  - Celtic Foyer
- **08:00-12:00** Morning Sessions
  - Celtic Ballroom
  - Breakout session B
    - 1. Mulligan
    - 2. RTJ
Friday October 12\textsuperscript{th}

17:00  Welcome reception

19:00  Dinner

19:30  \textbf{Acute-on-chronic liver failure}

\emph{by} Rajiv Jalan (University College London, UK)

Saturday October 13\textsuperscript{th}

\section*{SESSION 1 – HEPATIC ENCEPHALOPATHY}

\textbf{Chairs :} \textit{Rajiv Jalan (University College London)}

\textit{Puneeta Tandon (University of Alberta)}

\textbf{Learning Objectives}

At the end of this session, participants will/will be able to:

\begin{itemize}
  \item Review the underlying pathophysiological mechanisms of hepatic encephalopathy
  \item Recognize the impact of hepatic encephalopathy on relevant clinical outcomes
  \item Understand the influence of the etiology of cirrhosis on cognitive decline
  \item Review current management strategies for hepatic encephalopathy
\end{itemize}

8:00  \textbf{Gut-liver-brain axis}

\emph{by} Christopher Rose (CRCHUM, Montréal, Québec)

8:30  \textbf{Cognitive decline pre-cirrhosis}

\emph{by} Mark Swain (University of Calgary, Calgary, Alberta)

9:00  \textbf{Diagnosis and management of hepatic encephalopathy}

\emph{by} Jasmohan Bajaj (Virginia Commonwealth University, USA)

9:30  \textbf{Coffee break}
SESSION 2 – BLEEDING AND COAGULOPATHY IN CIRRHOSIS

Chairs: Jody Olson (University of Kansas Medical Center)  
Julia Wendon (Kings College Hospital)

Learning Objectives
At the end of this session, participants will/will be able to:

- Discuss endoscopic and non-invasive variceal screening methods in decompensated cirrhosis
- Review the management of variceal bleeding
- Understand abnormalities in coagulation/hemostasis in decompensated cirrhosis
- Evaluate the role of anticoagulation in cirrhotic patients with thromboembolic complications

10:00 Primary variceal screening: Is endoscopy required?  
by Juan Abraldes (University of Alberta, Edmonton, Alberta)

10:30 Management of variceal bleeding  
by Julien Bissonnette (CHUM, Montréal, Québec)

11:00 When to treat portal vein thrombosis  
by Vladimir Marquez (Vancouver General Hospital, Vancouver, British Columbia)

11:30 Coagulopathy in cirrhosis  
by Todd Stravitz (Virginia Commonwealth University, USA)

12:00 Lunch
**Session 3 – Muscle and Nutrition in Cirrhosis**

**Chairs:**  
*Jasmohan Bajaj (Virginia Commonwealth University)*  
*Scott Nyberg (Mayo Clinic)*

**Learning Objectives**

At the end of this session, participants will/will be able to:

- Understand the impact of sarcopenia in cirrhosis
- Review current concepts about nutrition in cirrhosis/ACLF
- Describe the role of palliative care in ACLF/cirrhotic patients declined for liver transplant
- Recognize the impact of HE on driving

**13:30**  
**Impact of sarcopenia**  
*by Aldo Montano-Loza (University of Alberta, Edmonton, Alberta)*

**14:00**  
**Nutrition and cirrhosis**  
*by Manuela Merli (Sapienza University of Rome, Italy)*

**14:30**  
**Breakout session A**

1. **Hepatic encephalopathy and driving**  
*by Phil Wong (McGill University, Montréal, Québec)*

2. **Palliative care in the cirrhotic patient**  
*by Puneeta Tandon and Amanda Brisebois (University of Alberta, Edmonton, Alberta)*

**15:30**  
**Coffee break**
SESSION 4 – CRITICAL CARE AND LIVER TRANSPLANT IN THE ACLF PATIENT

Chairs:  
*Patrick Kamath (Mayo Clinic)*  
*Michael Lucey (University of Wisconsin)*

Learning Objectives
At the end of this session, participants will/will be able to:

- Discuss critical care management of the ACLF patient with multi-organ failure
- Review the evidence for artificial/bioartificial liver support in ACLF
- Review perioperative challenges in the ACLF patient undergoing liver transplant
- Understand the challenges of determining futility in ACLF patient undergoing liver transplantation

16:00  
**Critical care management of the ACLF patient in the ICU**  
*by Julia Wendon (King’s College Hospital, UK)*

16:30  
**Artificial liver support**  
*by Scott Nyberg (Mayo Clinic, USA)*

17:00  
**Perioperative management during liver transplantation**  
*by François Carrier (CHUM, Montréal, Québec)*

17:30  
**Liver transplant: Challenges in predicting futility**  
*by Dean Karvellas (University of Alberta, Edmonton, Alberta)*

19:00  
**Reception**

20:00  
**Dinner**

20:30  
**Towards a unified definition and future research opportunities**  
*by Patrick Kamath (Mayo Clinic, USA)*
Sunday October 14th

**SESSION 5 – COMPLICATIONS AND TREATMENTS**

**Chairs:**  
Marc Bilodeau (CHUM)  
Mark Swain (University of Calgary)

**Learning Objectives**

At the end of this session, participants will/will be able to

- Review the epidemiology and therapies of acute kidney injury (AKI) in cirrhosis
- Recognize the impact of sepsis in cirrhosis and the rational use of antibiotics
- Understand the role and challenges of Hepatitis C Virus (HCV) eradication in decompensated cirrhosis
- Discuss evolving role of liver transplant in patients with alcohol-related liver disease

8:00  Breakout session B

1. Sepsis and antimicrobials: A clinical challenge  
   *by Jody Olson (University of Kansas Medical Center)*

2. Controversies in liver transplantation: Alcoholic hepatitis  
   *by Michael Lucey (University of Wisconsin, USA)*

9:00  Hepatorenal syndrome/AKI in cirrhosis  
   *by Florence Wong (University Health Network, Ontario)*

9:30  Benefit of hepatitis C treatment in decompensated cirrhosis  
   *by Jordan Feld (University Health Network, Ontario)*

10:00  Coffee break

**SESSION 6 – INTERACTIVE SESSION**

10:30  Case reports with “live” survey

12:00  End of the meeting

13:30  Mini-putt tournament
Rajiv Jalan is a clinical-academic whose main interest is in better understanding the molecular pathogenesis of acute on chronic liver failure. He was amongst the first to recognise the existence of this syndrome and has worked to create the EASL-CLIF Consortium, which has performed studies to define acute on chronic liver failure clinically, pathophysiologically and prognostically. His present focus is on translating his research findings into new therapies and has discovered novel approaches to the prevention and treatment of this syndrome. His H-index is 81 and he is currently the Editor in Chief of Journal of Hepatology.
Notes
Gut-liver-brain axis

Christopher Rose, PhD
Professor, Department of Medicine
Université de Montréal, CRCHUM, Québec, Canada

Dr. Christopher Rose is currently Professor in the Department of Medicine at the Université de Montréal. He is director of the Hepato-neuro laboratory which is located at centre de recherche du centre hospitalier de l’Université de Montréal (CRCHUM). Dr. Rose received his PhD (Neuroscience) from Université de Montréal in 2000. He continued his research interests in Europe by pursuing post-doctoral studies in Germany, Spain and Norway. Dr. Rose’s research interests lie within the area of hepatic encephalopathy (HE), a field in which he has been researching for over 25 years. Translational research is the primary objective of Dr. Rose’s laboratory and, therefore, his research program is based on a bench-to-bedside concept. Dr. Rose has a vested interest in identifying the pathogenic factors and the pathophysiological pathways involved in the development of cerebral complications associated with liver disease which ultimately will lead to novel therapeutic approaches, improving the management of patients with liver disease as well as neurological outcome post-liver transplantation. Dr. Rose’s laboratory is currently funded by the CIHR, the CLF and the Québec Health Research Foundation (FRQS). Dr. Rose has published over 75 scientific articles and over 60 students at all levels from throughout the world have trained in his laboratory. Dr. Rose is currently co-chair of the Research Committee of the CASL and an executive committee member of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
Cognitive decline pre-cirrhosis

Mark Swain, MD, MSc, FRCPC, FAASLD

Professor of Medicine

University of Calgary, Alberta, Canada

Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, Canada. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on two main areas: (i) deciphering how inflammatory liver diseases cause symptoms such as fatigue, impaired cognition ("brain fog") and altered mood (depression and anxiety), and (ii) delineating the role of the innate immune system in regulating hepatic inflammation. His clinical research interests are focused in the areas of fatty liver disease (NAFLD), autoimmune liver disease and viral hepatitis.
Diagnosis and management of hepatic encephalopathy

Jasmohan Bajaj, MD

Associate Professor

Virginia Commonwealth University, Virginia, USA

Dr. Bajaj earned his MBBS from Delhi University at Maulana Azad Medical College. He completed an internship in internal medicine at Delhi University at Maulana Azad Medical College and internal medicine residency at the State University of New York Health Science Center in Brooklyn. He furthered his medical training with a fellowship in gastroenterology and Hepatology at the Medical College of Wisconsin Affiliated Hospitals, then went on to earn an MS in epidemiology at the Medical College of Wisconsin in Milwaukee. Active in research, Dr. Bajaj has served as a principal investigator or co-investigator for numerous clinical trials in areas such as hepatic encephalopathy, chronic liver disease and microbiome. His work has been published in Nature, Gastroenterology, Hepatology, the American Journal of Gastroenterology and Liver Transplantation, among others. Dr. Bajaj is an Associate Editor for the American Journal of Gastroenterology and is on the editorial board for the Journal of Hepatology, Hepatology and Liver Transplantation. He was elected to the American Society for Clinical Investigation and is a Fellow of the Royal College of Physicians in London. Dr Bajaj is currently the President of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism and is also the Chairperson for the North American Consortium for the Study of End-Stage Liver Disease.
Primary variceal screening: Is endoscopy required?

Juan Abraldes, MD

Professor of medicine
University of Alberta, Alberta, Canada

Dr. Juan G. Abraldes is Professor at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004), gaining experience in pre-clinical models of portal hypertension and cirrhosis. He was a faculty member of the Hepatic Hemodynamic Laboratory and the Liver Unit, at Hospital Clinic Barcelona, until 2013, when he moved to Alberta. He is now co-director of the Cirrhosis Care Clinic of the University of Alberta. He has published over 150 papers on the pathophysiology, diagnosis and management of portal hypertension. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis.
Julien Bissonnette, MD

Clinical hepatologist

CHUM,
Québec, Canada

Julien Bissonnette practices as a clinical hepatologist at the CHUM in Montreal. He has completed his medical degree and internal medicine residency at Université de Montréal. He has completed a fellowship with the financial support of the Canadian Liver Foundation in portal hypertension and vascular liver diseases in Hôpital Beaujon in Clichy, France under the supervision of Pr Dominique Valla with complementary formation in biostatistics at Université Pierre et Marie Curie in Paris, France. His main interests are portal hypertension, hepatic encephalopathy and hepatic vein catheterization.
When to treat portal vein thrombosis

Vladimir Marquez, MDCM, MSc, FRCP

Clinical Assistant Professor

Vancouver General Hospital,
British Columbia, Canada

Dr. Vladimir Marquez is a gastroenterologist and transplant hepatologist at the Vancouver General Hospital. He joined the staff at VGH as clinical assistant professor in 2014. Outside the field of transplantation, his clinical interests and expertise gravitate around the area of portal hypertension and the vascular disorders of the liver. He is an editorial board member of the Canadian Liver Journal.
I received my MD at New York University, and residency in internal medicine at the University of North Carolina at Chapel Hill. My fellowships in gastroenterology and transplant hepatology were at Virginia Commonwealth University in Richmond, where I have been on the faculty for 25 years. My primary research interest in the last 7 years has been hemostasis in patients with cirrhosis and acute liver failure. I am a Principle Investigator of the Acute Liver Failure Study Group, in which I have been a funded member for 18 years.
Dr. Montano-Loza obtained his undergraduate training at the “Universidad de Guadalajara”, in Mexico, where he graduated with an MD degree in 1998. Then, he completed his Internal Medicine residency and Gastroenterology & Endoscopy training at the “Instituto Nacional de Ciencias Medicas y Nutricion”, in 2005, and obtained a Master Degree in Medical Science at the “Universidad Autonoma de Mexico”. He went to obtained further training in Autoimmune Liver Diseases under the mentorship of Dr. Albert J. Czaja at the Mayo Clinic in Rochester Minnesota in 2008, and in 2009 he finished another Fellowship in Advanced Hepatology and Liver Transplantation at the University of Alberta under the mentorship of Dr. Vincent G. Bain. He obtained his PhD in Medical Science in 2013. He was the recipient of the International Travel Training Grant from the American College of Gastroenterology in 2006 and the Clinical Research Award from the American College of Gastroenterology in 2011, and the Canadian National Transplant Research Program Innovation Grant Award in 2018. He has written over 100 original publications and book chapters, largely in the areas of his major interest: autoimmune liver diseases and liver transplantation. He was elected president of the Canadian Liver Transplant Network in 2017. Since 2009, Dr. Montano-Loza has joined the department of Medicine as Assistant Professor at the University of Alberta, and he was promoted to Associate Professor in 2015.
Main research lines of Prof Merli are in the field of liver cirrhosis and liver transplantation with particular focus on nutrition and metabolism, portal hypertension, hepatic encephalopathy, bacterial infections. In these fields she has been invited speaker in national and international Congress. She is EASL member and honorary member of the European Society of Parenteral and Enteral Nutrition, working at present in the guidelines for nutrition in Liver disease for both these societies. Prof Merli published 195 original articles in international peer reviewed journal and 37 book chapters in the field of Gastroenterology and Hepatology (Scopus/ 6352 citation/HI44).
Palliative care in the cirrhotic patient

Dr. Tandon is an Associate Professor of Medicine, Co-Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. Her clinical practice and research are focused on cirrhosis with research interests including cirrhosis related complications, malnutrition, frailty, exercise therapy, palliative care and integrative health approaches such as meditation. It is her career goal to provide wholistic, interdisciplinary, patient-centered care through education, empowerment, engagement and team-work.
Dr. Amanda Brisebois is an Internal Medicine and Palliative Care Specialist, who works in Edmonton, Alberta, Canada. Since 2000, she has been practicing General Internal Medicine. She also is a certified Palliative Care Specialist since 2012. Her focused area of research and interest is now in non-cancer palliative care, and in integrating that care through patient transitions. She currently has co-founded a palliative cirrhosis clinic with Dr. Tandon (Hepatology) at the University of Alberta. She has published in this space, and is collaborating on multiple research projects in these areas. Dr. Brisebois is currently an Associate Clinical Professor at the University of Alberta, and the Medicine Facility Chief at the Grey Nuns Hospital in Edmonton.
Hepatic encephalopathy and driving

Philip Wong, MD, MSc

Associate Professor of Medicine and Hepatologist-Gastroenterologist

McGill University, Québec, Canada

Dr. Wong is from Saskatchewan, where he was a pharmacist before medical school, and completed training in Internal Medicine. From there, he did his GI training in Montreal at McGill University, with General Hepatology training in Winnipeg at the University of Manitoba, and then Liver Transplantation at the University of Toronto. A Master’s degree in Epidemiology and Biostatistics followed at McGill University and after a 2 year stint on staff at the University of Toronto Multi-organ transplant program, he and his family returned to McGill in 2006, where he is an Associate Professor of Medicine, and Hepatologist-Gastroenterologist. He serves as the Site Director of the Department of Gastroenterology at the Royal Victoria Hospital. Dr. Wong’s research interests include outcomes in liver transplantation, viral hepatitis, fatty liver and cirrhosis and its complications.
Critical care management of the ACLF patient in the ICU

Julia Wendon, MBChB, MRCP, FRCP

Professor, Medical Director

Kings College Hospital, UK

Consultant in hepatology and Intensive care since 1992 at Kings College Hospital, subsequent clinical director of Critical Care Services. Research interest in prognostic models, and treatment and management of organ dysfunction and more recently immune dysfunction of liver failure and possible interventions. A clinician and enthusiast.
Dr. Scott Nyberg is professor of Surgery, Professor of Biomedical Engineering and a Consultant in Transplantation Surgeon at the Mayo Clinic in Rochester, Minnesota. The overall goal of his research program is to develop cell-based and regenerative therapies for the treatment of patients with liver failure and metabolic liver disease. He is uniquely trained as a liver transplant surgeon and a biomedical engineer. His laboratory has extensive expertise in the isolation and cultivation of primary hepatocytes for use in cellular therapies. His team has designed and tested several bioartificial liver devices including our current device - the Spheroid Reservoir Bioartificial Liver (SRBAL). In parallel, they have genetically engineered pigs with a homozygote deficiency in fumarylacetocacetate hydrolase (FAH-/-). These pigs are the first large animal model of a hereditary metabolic liver disease, hereditary tyrosinemia type 1 (HT1). Along with tyrosinemia, the phenotype of FAH-/- pigs includes spontaneous cirrhosis and portal hypertension. FAH-/- pigs may also serve as in vivo incubators for production of human hepatocytes. Fetal and young FAH-/- pigs may facilitate maturation of human induced pluripotent (iPS) stem cells to hepatocytes. His laboratory has been consistently funded by the National Institute of Health (NIH). Dr. Nyberg has published 185 papers in peer reviewed journals and has a current H-index of 46.
Perioperative management during liver transplantation

François Carrier, MD

Anesthesiologist-intensivist and assistant clinical professor

CHUM, Québec, Canada

Dr. Carrier graduated in Medicine from Université Laval in 2003, is a specialist in anesthesiology (Université Laval - 2008) and in intensive care medicine (Université de Montreal - 2009). He completed a fellowship in liver transplantation and hepatobiliary intensive care at Paul Brousse Hospital, Villejuif, France (2009-2010) and is board-certified in advanced perioperative echocardiography from the American College of Echocardiography. Dr. Carrier is an anesthesiologist and intensivist at the Centre Hospitalier de l’Université de Montréal (CHUM) and is an assistant clinical professor at Université de Montréal. He is a researcher at the CHUM Research Center and leads a new research program on the role of different perioperative interventions on post-operative outcomes in liver transplantation. He has also some interests in critical liver failure and transfusion medicine.
Dean Karvellas, MD, SM, FRCPC, FCCM

Associate Professor of Medicine
University of Alberta, Alberta, Canada

Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is the Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.
Towards a unified definition and future research opportunities

Patrick Kamath, MD

Professor of Medicine

Mayo Clinic, Minnesota, USA

The research interests of Patrick S. Kamath, M.D., focus on acute-on-chronic liver failure, nonalcoholic fatty liver disease, polycystic liver disease, Budd-Chiari syndrome and hereditary hemorrhagic telangiectasia. Dr. Kamath also studies alcoholic hepatitis, cirrhosis and the complications thereof, including portal hypertension, variceal hemorrhage, ascites and hepatic encephalopathy. Dr. Kamath works to improve understanding of the mechanisms and complications of liver disease, in the hopes of developing new strategies of prevention and treatment that will improve quality of life and overall outcomes for patients with various liver diseases. The MELD score that he helped develop is used worldwide as a prognostic score for liver disease. His current focus is on finding ways to improve survival in patients with acute-on-chronic liver failure. He is also dedicated to the education of the next generation of physicians, who will further advance this work.
Dr Michael Ronan Lucey was born in Dublin, Ireland, and was educated at Trinity College, Dublin, graduating with the degrees of M.B., B.Ch in 1976. He was awarded an M.D. by thesis in 1985. He completed his internship at the Meath Hospital, Dublin and residency in Internal Medicine at the Federated Dublin Voluntary Hospitals. He was a fellow in Gastroenterology at Saint Bartholomew's Hospital, and a fellow in Liver Diseases in Kings College Hospital, both in London, England. In 1985 he came to the University of Michigan, first as a fellow and then as faculty in the Division of Gastroenterology. While at the University of Michigan, he became Medical Director of the Liver Transplant program. From 1995 to 2001, he was Director of Hepatology at the University of Pennsylvania. In 2001 he became Professor of Medicine, Chief of the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. Dr Lucey's research interests include selection for and outcome of liver transplantation, alcoholic liver disease, and management of end-stage liver disease. Dr Lucey was president of the American Society of Transplantation in 2003. He was treasurer of the American Association for the Study of Liver Diseases from 2007 to 2010. He was Editor in Chief of Clinical Liver Disease, the on-line educational journal of the AASLD from 2011 to 2017.
Sepsis and antimicrobials: A clinical challenge

Jody Olson, MD, FACP

Associate Professor of Medicine and Surgery

University of Kansas Medical Center, Kansas, USA

Jody Olson is an Associate Professor of Medicine and Surgery at the University of Kansas Medical Center in Kansas City, Kansas. He attended medical school at the University of Nebraska Medical Center. He completed his internal medicine residency at the University of Minnesota under the CDC sponsored Global Health Pathway. After residency he completed advanced fellowships in Critical Care Medicine and Transplant Hepatology at Mayo Clinic in Rochester, Minnesota. Currently he practices both general and transplant hepatology and is an intensivist providing ICU care for both liver transplant patients and hepatobiliary surgery patients. His clinical research interests are centered on the intensive care management of patients with advanced liver disease.
Hepatorenal syndrome/AKI in cirrhosis

Florence Wong, MD

Full Professor, Hepatologist

University Health Network (Toronto), Ontario, Canada

Florence Wong, MD is a Full Professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 26 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research (CIHR), Canadian Liver Foundation (CLF) and the National Institutes of Health. She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, She also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver (CASL). Recently, she served as the Chair of the “Acute-on-Chronic Liver Failure Special Interest Group” of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the CLF and the CASL for her contribution to academia in Hepatology. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics.
Benefit of hepatitis C treatment in decompensated cirrhosis

Jordan Feld, MD

Associate Professor of Medicine

University Health Network (Toronto), Ontario, Canada

Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Currently, Dr. Feld is clinician-scientist based at the Toronto General Hospital, Toronto Centre for Liver Disease and the McLaughlin-Rotman Centre for Global Health.
Canadian Liver Foundation

LIVERight Gala

Join us for the LIVERight Gala, a fundraising event that offers guests a night of top notch entertainment and gourmet food in 6 cities across the country:

- **Vancouver** – Saturday, November 24, 2018 at the Fairmont Hotel
- **Calgary** – Friday, November 23, 2018 at the Sheraton Cavalier
- **Toronto** – Friday, November 16, 2018 at the Westin Harbour Castle Hotel
- **Ottawa** – Thursday, November 22, 2018 at the Ottawa Conference & Event Centre
- **Montréal** – Saturday, November 17, 2018 at the Rialto Theatre
- **Halifax** – Friday, November 30, 2018 at the Halifax Marriott Harbourfront Hotel

Visit liver.ca/liveright-gala to find out more!